Microbot Reports Q2 2026 Revenue and Customer Growth Over 100% QoQ, Expanding Commercial Footprint

What happened

Microbot Medical reported over 100% sequential growth in revenue and new customers for Q2 2026, alongside rising LIBERTY procedure volumes since the Full Market Release in April. The company plans to grow U.S. sales territories from 8 to 12 and enter international markets by year-end 2026, citing heightened demand from leading health systems. While this marks a positive early indicator for the LIBERTY commercialization thesis, absolute revenue remains undisclosed and likely low, so the data point does not yet confirm a durable multi-site adoption trajectory.

Implication

The Q2 2026 update provides the first observable revenue growth from LIBERTY commercialization, moving beyond the 'pre-revenue' stage. However, without disclosed absolute revenue figures or the number of paying sites, the magnitude of traction remains uncertain. Investors should demand further transparency in upcoming quarters, specifically the number of hospitals and recurring disposable revenues, to justify a higher valuation. The expansion plans signal management confidence, but execution risk persists given heavy dilution and the need to convert interest into sustainable adoption.

Thesis delta

The DeepValue report priced in minimal revenue visibility; the >100% QoQ growth introduces early positive evidence that commercialization is gaining traction, but the sample size is too small to shift from WAIT to a constructive BUY. The base case remains that adoption progresses mainly in top academic centers, and this news aligns with that scenario. The primary risk—that LIBERTY fails to gain multiple paying sites—has modestly decreased, but the thesis remains contingent on sustained disclosure of site count and disposable pull-through in subsequent quarters.